WO1996037214A2 - Compositions of interleukin and pyrimidine nucleosides - Google Patents
Compositions of interleukin and pyrimidine nucleosides Download PDFInfo
- Publication number
- WO1996037214A2 WO1996037214A2 PCT/EP1996/002088 EP9602088W WO9637214A2 WO 1996037214 A2 WO1996037214 A2 WO 1996037214A2 EP 9602088 W EP9602088 W EP 9602088W WO 9637214 A2 WO9637214 A2 WO 9637214A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- deoxy
- cytidine
- fluoro
- fluorocytidine
- pyrimidine nucleoside
- Prior art date
Links
- 239000002718 pyrimidine nucleoside Substances 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims description 15
- 102000015696 Interleukins Human genes 0.000 title description 2
- 108010063738 Interleukins Proteins 0.000 title description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 33
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 33
- 229940117681 interleukin-12 Drugs 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 239000012453 solvate Substances 0.000 claims abstract description 15
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 14
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 13
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003937 drug carrier Substances 0.000 claims abstract description 10
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 9
- 230000002195 synergetic effect Effects 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- -1 hydrocarbon radical Chemical class 0.000 claims description 41
- 102000001853 Pyrimidine Phosphorylases Human genes 0.000 claims description 18
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 17
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 17
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
- 150000003254 radicals Chemical class 0.000 claims description 11
- 239000004215 Carbon black (E152) Substances 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 229930195733 hydrocarbon Natural products 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 150000005840 aryl radicals Chemical class 0.000 claims description 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 4
- 229940045145 uridine Drugs 0.000 claims description 4
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- KCMJXAWSWXCEGZ-XPWNBWMWSA-N pentyl 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C1=CC(C(=O)OCCCCC)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 KCMJXAWSWXCEGZ-XPWNBWMWSA-N 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 3
- YZOATMTVMAYOAQ-MDKSQSMOSA-N propyl 6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1h-pyrimidine-6-carboxylate Chemical compound C1=CC(C(=O)OCCC)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YZOATMTVMAYOAQ-MDKSQSMOSA-N 0.000 claims description 3
- ZJZVFCZVDKFJAS-UGKPPGOTSA-N 2,2-dimethylpropyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)N=C(NC(=O)OCC(C)(C)C)C(F)=C1 ZJZVFCZVDKFJAS-UGKPPGOTSA-N 0.000 claims description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- HMYGCRITZQDWHM-MJEGLDIISA-N 2-ethylhexyl 6-amino-3-[(2R,3R,4S,5S)-5-[fluoro(hydroxy)methyl]-3,4-dihydroxyoxolan-2-yl]-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C(O)F)O1 HMYGCRITZQDWHM-MJEGLDIISA-N 0.000 claims description 2
- NQJDADBILIAZPU-JLTWGVLTSA-N 2-phenylethyl 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C1=CC(N)(C(=O)OCCC=2C=CC=CC=2)NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NQJDADBILIAZPU-JLTWGVLTSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 125000001118 alkylidene group Chemical group 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- QXHOURZGPBKDOG-QLJSRWMYSA-N hexyl 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C1=CC(C(=O)OCCCCCC)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QXHOURZGPBKDOG-QLJSRWMYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- SUYDMEPUJZFGLM-XPWNBWMWSA-N 3-methylbutyl 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C1=CC(C(=O)OCCC(C)C)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SUYDMEPUJZFGLM-XPWNBWMWSA-N 0.000 claims 2
- 108010054917 Pyrimidine Phosphorylases Proteins 0.000 claims 2
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- PYHJXYZEEPKYOC-MDKSQSMOSA-N 2-methoxyethyl 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C1=CC(C(=O)OCCOC)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 PYHJXYZEEPKYOC-MDKSQSMOSA-N 0.000 claims 1
- UBSCVULUOZPVTN-AMSAUXSNSA-N 2-methylpropyl 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C(C(C)C)OC(=O)C1(NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=C1)=O)N UBSCVULUOZPVTN-AMSAUXSNSA-N 0.000 claims 1
- XCEAOYHJEQDYJM-YGVNHVFTSA-N 4-fluoroheptyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-2-oxopyrimidin-4-yl]carbamate Chemical compound FC(CCCOC(=O)NC1=NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=C1)=O)CCC XCEAOYHJEQDYJM-YGVNHVFTSA-N 0.000 claims 1
- BXINEIOMHUPEJI-XVURIDPWSA-N 4-fluorohexyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-2-oxopyrimidin-4-yl]carbamate Chemical compound FC(CCCOC(=O)NC1=NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=C1)=O)CC BXINEIOMHUPEJI-XVURIDPWSA-N 0.000 claims 1
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical compound FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 31
- 229950005454 doxifluridine Drugs 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 19
- 108030006145 Pyrimidine-nucleoside phosphorylases Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229960004117 capecitabine Drugs 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 201000008808 Fibrosarcoma Diseases 0.000 description 5
- 201000008274 breast adenocarcinoma Diseases 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- PKOFILUUDJQYRV-BMLYNZSSSA-N 2-ethylbutyl 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoro-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C(C)C(COC(=O)C1(NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=C1F)=O)N)CC PKOFILUUDJQYRV-BMLYNZSSSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000005699 fluoropyrimidines Chemical class 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- BDPHEOFPHIHPJA-UGKPPGOTSA-N 2-methylpropyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate Chemical compound C1=C(F)C(NC(=O)OCC(C)C)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 BDPHEOFPHIHPJA-UGKPPGOTSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005975 2-phenylethyloxy group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WJANXDCMANSWCT-WGAYBCHKSA-N 3,3-dimethylbutyl 6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoro-2-oxo-1h-pyrimidine-6-carboxylate Chemical compound C1=C(F)C(C(=O)OCCC(C)(C)C)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WJANXDCMANSWCT-WGAYBCHKSA-N 0.000 description 1
- PPVCPOIDSSQXMR-UORFTKCHSA-N 3-methylbutyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate Chemical compound C1=C(F)C(NC(=O)OCCC(C)C)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 PPVCPOIDSSQXMR-UORFTKCHSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001197446 Mus cypriacus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102000006405 Uridine phosphorylase Human genes 0.000 description 1
- 108010019092 Uridine phosphorylase Proteins 0.000 description 1
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VFRJKOSAZBWSKR-JKGQPHCRSA-N butyl 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C1=C(F)C(C(=O)OCCCC)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 VFRJKOSAZBWSKR-JKGQPHCRSA-N 0.000 description 1
- 229940085837 capecitabine 150 mg Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- FMPHIVCWEXSQON-PCLXQLDZSA-N cyclohexylmethyl 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C1(CCCCC1)COC(=O)C1(NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=C1F)=O)N FMPHIVCWEXSQON-PCLXQLDZSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- MRCCJZAFDGHCBP-QGMIFYJMSA-N cyclohexylmethyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)N=C(NC(=O)OCC2CCCCC2)C(F)=C1 MRCCJZAFDGHCBP-QGMIFYJMSA-N 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- UPXYTMFXFQFRAI-IPSUOGRTSA-N heptyl 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1H-pyrimidine-6-carboxylate Chemical compound C(CCCCCC)OC(=O)C1(NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=C1)=O)N UPXYTMFXFQFRAI-IPSUOGRTSA-N 0.000 description 1
- CYXWQMGIIQZTTI-XIDUGBJDSA-N hexyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate Chemical compound C1=C(F)C(NC(=O)OCCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 CYXWQMGIIQZTTI-XIDUGBJDSA-N 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VBIWKKWAZUNTHT-SMGXOBOGSA-N n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-2-(1h-indol-2-yl)acetamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)N=C(NC(=O)CC=2NC3=CC=CC=C3C=2)C(F)=C1 VBIWKKWAZUNTHT-SMGXOBOGSA-N 0.000 description 1
- IRHHXZDOVVASFR-LHNIVKCTSA-N n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]hexanamide Chemical compound C1=C(F)C(NC(=O)CCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 IRHHXZDOVVASFR-LHNIVKCTSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- OJLIMLARCDSSCZ-PNHWDRBUSA-N propyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate Chemical compound C1=C(F)C(NC(=O)OCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 OJLIMLARCDSSCZ-PNHWDRBUSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention is concerned with a novel pharmaceutical composition. More particularly, this invention is concerned with a synergistic antitumor pharmaceutical composition comprising an effective amount of interleukin- 12 (IL-12) and a pyrimidine nucleoside, as well as a hydrate or solvate thereof, that is converted into fluorouracil or its derivative, and pharma ⁇ ceutically acceptable carrier, a synergistic antitumor pharmaceutical composition for the treatment of various cancer and a method of treating various cancers.
- IL-12 interleukin- 12
- a pyrimidine nucleoside as well as a hydrate or solvate thereof, that is converted into fluorouracil or its derivative
- pharma ⁇ ceutically acceptable carrier a synergistic antitumor pharmaceutical composition for the treatment of various cancer and a method of treating various cancers.
- doxifluridine 5'-Deoxy-5-fluorouridine
- doxifluridine a pyrimidine nucleoside
- Doxifluridine is converted into the active drug 5-FU by pyrimidine nucleoside phosphorylases (PyNPase) in vivo, both thymidine and uridine phosphorylases. Therefore, PyNPase is essential for the efficacy of doxifluridine. In fact, tumors with very low levels of this enzyme were refractory to doxifluridine, and PyNPase gene transfection made the tumors more susceptible to this drug.
- IL-12 up-regulates PyNPase activity in tumor tissues and consequently enhances the antitumor activity of doxifluridine.
- IL-12 also enhanced the activity of 5'-deoxy-5-fluoro-N4-(n- pentylcarbonyl)cytidine (capecitabine), which generates doxifluridine and is then converted to 5-FU by PyNPase.
- IL-12 enhanced the anti ⁇ tumor activity of 5-FU to a lesser extent than the anti-tumor activity of doxifluridine.
- cytokines such as IL-la, TNF-a and IFN-g up-regulate PyNPase activity in tumor cell cultures and consequently enhance the susceptibility to doxifluridine (cf. Eda et al. Cancer Chemother Pharmacol. (1993) 32:333-339, and Jpn. J. Cancer Res. 84, 341- 347, March 1993).
- cytokines when given parenterally are distributed to various normal tissues through the circulation and cause systemic side effects, such as flu-like syndrome, leukopenia, hypotension, etc.
- these cytokines distributed to normal tissues as well as tumor tissues would enhance PyNPase activity there and make both the normal and tumor tissues more susceptible to doxifluridine. Therefore, these cytokines would enhance both the efficacy and toxicity of doxifluridine when given in combination.
- IL-12 given parenterally however, induced much higher levels of IFN-g in tumor tissues than in normal tissues. Therefore, IL-12 given parenterally enhances PyNPase activity preferentially in tumor tissues without causing IFN-g-associated systemic side effects.
- the pyrimidine nucleoside is an uridine, cytidine or its derivative represented by the following formula (I) or (II), respectively
- R ⁇ is hydrogen or an radical which is easily hydrolyzable under physiological conditions
- R-2 is hydrogen, cyano, fluorine,lower alkyl or lower alkylidene which may be substituted with one or two fluorine atom(s), or O l
- B ⁇ is lower alkyl, h droxymethyl, or CH2OR 1 , as well as a hydrate or solvate thereof.
- Preferred radicals which are easily hydrolyzable under physiological conditions of Rl in the above formulae (I) and (II) are R ⁇ CO-, R ⁇ OCO- or R SCO- wherein R 4 is alkyl, cycloalkyl, aralkyl or aryl.
- preferred alkyl, cycloalkyl, aralkyl or aryl radical represented by R 4 are a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven], or a radical of the formula (CH2)n-Y[ n which n is an integer from 0 to 4, when Y is cyclohexyl, or n is an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl] .
- a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven]" preferably signifies n-propyl, l-isopropyl-2-methylpropyl, 1,1,2-trimethylpropyl, n-butyl, isobutyl, 2-ethylbutyl, 3,3-dimethylbutyl, n-pentyl, isopentyl, neopentyl, 2-propylpentyl, n-hexyl, 2-ethylhexyl, n-heptyl, allyl, 2-buten-l-yl, 3-buten-l-yl, 3-penten-l-yl, 4-penten-l-yl, 3-hexen-l-yl, 4-hexen-l-yl, 5 hexen-1-yl, and the like.
- a radical of the formula (CE_2)n-Y [in which n is an integer from 0 to 4, when Y is a cyclohexyl radical, or n is an integer from 2 to 4, when Y is a lower alkoxy radical having from 1 to 4 carbon atom(s) or a phenyl radical]" preferably siginifies cyclohexyl, cyclohexylmethyl,
- Preferred pyrimidine nucleoside for the present invention are:
- IL-12 is a heterodimeric cytokine which is produced by antigen presenting cells and serves as a pivotal regulator of T and NK cell function (cf. Stern, A.S. et al. Proc. Natl. Acad. Sci. USA. (1990) 87, 6808-6812 and Kobayashi, M. et al. J. Exp. Med. (1989) 170, 827-845).
- Biological activities associated with IL-12 include its ability to enhance the lytic activity of natural killer/lymphokine activated killer cells, to induce the secretion of interferon-g (IFN-g) by both resting and activated T and NK cells, to stimulate the proliferation of activated T and NK cells, to facilitate cytotoxic T lymphocyte responses and to play a critical and unique role in promoting Th-1 type cytokine responses, thereby facilitating cell-mediated immunity (cf. Brunda, M. J. J. Leukocyte Biol. (1994) 55, 280-288 and Taniguchi, G. Blood (1994) 84, 4008-4027).
- IFN-g interferon-g
- IL-12 both human type and murine type, is composed of two disulfide- bonded glycoprotein subunits approximately 35 KDa and 40 KDa in size.
- cDNAs encoding each subunit of IL-12 have been cloned and coexpressed in Chinese Hamster Ovary (CHO) cells to yield the secreted, bioactive, heterodimeric lymphokine (Gubler, U. et al. Proc. Natl. Acad. Sci. USA. (1991) 88, 4143-4147 and Schaenhaut, D.S. et al. J. Immunol. (1992) 148, 3433- 3440)
- a clone of transfected CHO cells secreting recombinant IL-12 was selected.
- Recombinant IL-12 was purified from the culture supernatant of CHO cells grown in a serum-free medium, by ion exchange and gel filtration chromatography.
- the pharmaceutical compostion of the present invention can be administered in any form, for example, tablets, pills, suppositories, capsules, granules, powders, etc. or emulsions.
- the pharmaceutical composition of the present invention are especially suitable for intramuscular, subcutaneous, or intravenous administration.
- Pharmaceutically acceptable carriers and excipients useful in formulating the pharmaceutical composition of the present invention are those commonly used.
- Pharmaceutically acceptable materials can be an organic or inorganic inert carrier material suitable for enteral, percutaneous or parenteral administration such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols and petroleum jelly.
- the pharmaceutical composition provided by the present invention can be administered orally, e.g.
- the administration can also be carried out parenterally, e.g. in form of sterile solutions, suspensions or emulsions; or locally, e.g. in form of solutions, suspensions, salves, powders or aerosols.
- the pharmaceutical composition can be sterilized and/or can contain further adjuvants such as preserving, stabilizing, setting, emulsifying agents, flavor-improving, salts for variation of the osmotic pressure or substances acting as buffers.
- the synergistic antitumor pharmaceutical composition of the present invention comprises a single pharmaceutical composition as well as a kit of pharmaceutical compositions each containing the individual active ingredient in a desirable dosage form, thus, the present invention is also concerned with a kit for the treatment of colorectal cancer, breast cancer, stomach cancer, lung cancer, cervical cancer, bladder cancer and other malignant diseases which comprises as a first pharmaceutical composition containing an effective amount of IL-12 and a pharmaceutically acceptable carrier, and as a second pharmaceutical composition containing an effective amount of pyrimidine nucleoside derivative, as well as hydrate or solvate thereof and a pharmaceutically acceptable carrier.
- Dosage ranges for the pharmaceutical composition of the present invention can easily be determined by one skilled in the art, and depend on the route of administration, the age, weight and condition of the patient and the particular disease to be treated.
- an approximate range from about 0.05 mg/body/day to about 500 mg/body/day of IL-12, and about 50 mg/body/day to about 20,000 mg/body/day of pyrimidine nucleoside generally range from about 1:100 to about 1:400,000.
- a weight ratio from about 1:1,000 to about 1:10,000 is preferred.
- Rectal administration and intravenous injection are preferred routes of administration of the pharmaceutical composition according to the present invention.
- compositions of the present invention are useful for the treatment of colorectal cancer, breast cancer, stomach cancer, lung cancer, cervicial cancer, bladder cancer, and other malignant diseases and the like.
- mouse IL-12 (mIL-12) at 0.1 mg/mouse or vehicle (0.1 mg/ml of mouse serum albumin dissolved in phosphate-buffered saline) daily for 7 days starting at day 7 and day 8, respectively, after the tumor inoculation.
- mIL-12 mouse IL-12
- vehicle 0.1 mg/ml of mouse serum albumin dissolved in phosphate-buffered saline
- PyNPase activity in the tumor tissues was measured as described in Eda et al. Cancer Chemother. Pharmacol. 1993; 32:333.
- Mouse IFN-g (m IFN-g) levels in the tumor tissue were also measured by a commercially available ELISA system (Intertest g, Genzyme).
- mIL-12 enhanced PyNPase activity 11.9 fold in A75 ⁇ tumors and 2.4 fold in Meth A tumors. This is probably the result of the up- regulation of mIFN-g, which is an up-regulator of PyNPase.
- mice were inoculated with A7 ⁇ mammary adenocarcinoma (2 x 10 5 cells). The mice were given s.c. mIL-12 at 0.1 mg/mouse or vehicle (0.1 mg/ml of mouse serum albumin dissolved in phosphate-buffered saline) daily for 7 days starting at day 6 after the tumor inoculation. One day thereafter, mIFN-g levels in the serum and tissue homogenates of tumor and other organs were measured by ELISA system as mentioned above.
- mIL-12 greatly increased mIFN-g levels in tumors as compared with those in normal organs.
- the tumor tissue level of mIFN-g is 3 to 7 fold higher than those of normal tissues so far examined and 50 fold higher than those in the circulation.
- A7 ⁇ (2 x 10 5 cells) was inoculated s.c. into female C ⁇ 7BL/6 mice.
- the mice were given mIL-12 (0.03 ⁇ g/mouse, s.c), doxifluridine (1.5 mmol/kg, p.o.) and their combination, daily for 4 weeks, starting from day 9 after the tumor inoculation.
- Doxifluridine as a single agent did not show activity in tumor growth inhibition because A75 ⁇ tumor has only low levels of PyNPase, whereas mIL-12 was effective (Table 3). mIL-12 in combination with doxifluridine was much more effective than mIL-12 alone and regressed the tumor.
- Control 28 (23 - 42) 0 o/ ⁇ doxifluridine 29 (22 - 36) 4 0/5
- Meth A fibrosarcoma (5 x 10 5 cells) was inoculated s.c. into male BALB/c mice.
- the mice were given doxifluridine (O. ⁇ mmol/kg, p.o.), capecitabine (1.0 mmol/kg, p.o.), ⁇ -fluorouracil (0.07 ⁇ mmol kg, p.o.), mIL-12 (0.03 ⁇ g/mouse, s.c), and their combination, daily for 3 weeks, starting from day 8 after the tumor inoculation.
- Example 1 illustrate a pharmaceutical preparation of the present invention and do not limit the scope of the present invention.
- a kit having the following components A and B for treatment of colorectal cancer was manufactured in a conventional manner: Component A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A synergistic antitumor pharmaceutical composition comprising an effective amount of interleukin-12 and a pyrimidine nucleoside derivative as well as a hydrate or solvate thereof that is converted into fluorouracil or its derivative, and a pharmaceutically acceptable carrier.
Description
Compositions of interleukin and pyrimidine nucleosides
This invention is concerned with a novel pharmaceutical composition. More particularly, this invention is concerned with a synergistic antitumor pharmaceutical composition comprising an effective amount of interleukin- 12 (IL-12) and a pyrimidine nucleoside, as well as a hydrate or solvate thereof, that is converted into fluorouracil or its derivative, and pharma¬ ceutically acceptable carrier, a synergistic antitumor pharmaceutical composition for the treatment of various cancer and a method of treating various cancers.
5'-Deoxy-5-fluorouridine (doxifluridine), a pyrimidine nucleoside, is effective in the treatment of various malignant diseases. Doxifluridine is converted into the active drug 5-FU by pyrimidine nucleoside phosphorylases (PyNPase) in vivo, both thymidine and uridine phosphorylases. Therefore, PyNPase is essential for the efficacy of doxifluridine. In fact, tumors with very low levels of this enzyme were refractory to doxifluridine, and PyNPase gene transfection made the tumors more susceptible to this drug. Now, it has surprisingly been found that IL-12 up-regulates PyNPase activity in tumor tissues and consequently enhances the antitumor activity of doxifluridine. IL-12 also enhanced the activity of 5'-deoxy-5-fluoro-N4-(n- pentylcarbonyl)cytidine (capecitabine), which generates doxifluridine and is then converted to 5-FU by PyNPase. In contrast, IL-12 enhanced the anti¬ tumor activity of 5-FU to a lesser extent than the anti-tumor activity of doxifluridine.
It has been reported that some inflammatory cytokines, such as IL-la, TNF-a and IFN-g up-regulate PyNPase activity in tumor cell cultures and consequently enhance the susceptibility to doxifluridine (cf. Eda et al. Cancer Chemother Pharmacol. (1993) 32:333-339, and Jpn. J. Cancer Res. 84, 341- 347, March 1993). These cytokines when given parenterally are distributed to various normal tissues through the circulation and cause systemic side effects, such as flu-like syndrome, leukopenia, hypotension, etc. In addition,
these cytokines distributed to normal tissues as well as tumor tissues would enhance PyNPase activity there and make both the normal and tumor tissues more susceptible to doxifluridine. Therefore, these cytokines would enhance both the efficacy and toxicity of doxifluridine when given in combination. IL-12 given parenterally, however, induced much higher levels of IFN-g in tumor tissues than in normal tissues. Therefore, IL-12 given parenterally enhances PyNPase activity preferentially in tumor tissues without causing IFN-g-associated systemic side effects.
In a preferred embodiment of the present invention, the pyrimidine nucleoside is an uridine, cytidine or its derivative represented by the following formula (I) or (II), respectively
wherein R^ is hydrogen or an radical which is easily hydrolyzable under physiological conditions; R-2 is hydrogen, cyano, fluorine,lower alkyl or lower alkylidene which may be substituted with one or two fluorine atom(s), or O l; and Bβ is lower alkyl, h droxymethyl, or CH2OR1, as well as a hydrate or solvate thereof.
Preferred radicals which are easily hydrolyzable under physiological conditions of Rl in the above formulae (I) and (II) are R^CO-, R^OCO- or R SCO- wherein R4 is alkyl, cycloalkyl, aralkyl or aryl.
Furthermore, preferred alkyl, cycloalkyl, aralkyl or aryl radical represented by R4 are a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven], or a radical of the formula (CH2)n-Y[ n which n is an integer from 0 to 4, when Y is cyclohexyl, or n is
an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl] .
In the above, the term "a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven]" preferably signifies n-propyl, l-isopropyl-2-methylpropyl, 1,1,2-trimethylpropyl, n-butyl, isobutyl, 2-ethylbutyl, 3,3-dimethylbutyl, n-pentyl, isopentyl, neopentyl, 2-propylpentyl, n-hexyl, 2-ethylhexyl, n-heptyl, allyl, 2-buten-l-yl, 3-buten-l-yl, 3-penten-l-yl, 4-penten-l-yl, 3-hexen-l-yl, 4-hexen-l-yl, 5 hexen-1-yl, and the like.
The term "a radical of the formula (CE_2)n-Y [in which n is an integer from 0 to 4, when Y is a cyclohexyl radical, or n is an integer from 2 to 4, when Y is a lower alkoxy radical having from 1 to 4 carbon atom(s) or a phenyl radical]" preferably siginifies cyclohexyl, cyclohexylmethyl,
2-cyclohexylethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 2-methoxyethyl, 2- ethoxyethyl, 2-propoxyethyl, 3-methoxypropyl, 3-ethoxypropyl, 4-methoxy- butyl, 4-ethoxybutyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, and the like.
Preferred pyrimidine nucleoside for the present invention are:
5'-deoxy-5-fluorouridine,
5-deoxy-5-fluorocytidine,
5'-deoxy-N -(3,5-dimethoxybenzoly)-5-fluorocytidine, 5'-deoxy-N -(3,5-dimethylbenzoly)-5-fluorocytidine,
5l-deoxy-N -[(2,4-dichlorophenyl)acetyl]-5-fluorocytidine,
5'-deoxy-N -(indol-2-ylacetyl)-5-fluorocytidine,
5'-deoxy-5-fluoro-N4-(3,4,5-trimethylbenzoly)cytidine,
5'-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-(hexyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N -(neopentyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4- [( 1, l,2-trimethylpropoxy)carbonyl] cytidine, δ'-deoxy-N4- [(3,3-dimethylbutoxy)carbonyl] -5-fluorocytidine, 5'-deoxy-5-fluoro-N4- [( l-isopropyl-2-methylpropoxy)carbonyl] cytidine, δ'-deoxy-N4- [(2-ethylbutyl)oxycarbonyl] -5-fluorocytidine,
N4- [(cyclohexylmethoxy)carbonyl] -5'-deoxy-5-fluorocytidine,
5'-deoxy-5-fluoro-N4- [(2-phenylethoxy)carbonyl] cytidine,
2',3'-di-0-acetyl-5,-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 2',3'-di-O-acetyl-N4-(butoxycarbonyl)-5,-deoxy-5-fluorocytidine, 2l,3'-di-0-benzoyl-N4-(butoxycarbonyl)-5'-deoxy-5-fluorocytidine, 2,,3'-di-0-acetyl-5,-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, 2',3'-di-0-acetyl-5'-deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine, 2,,3,-di-0-acetyl-5'-deoxy-5-fluoro-N4-(hexyloxycarbonyl)cytidine, 2,,3'-di-0-acetyl-5,-deoxy-N4-[(2-ethylbutyl)oxycarbonyl]-5-fluorocytidine, 2',3,-di-0-acetyl-N4-[(cyclohexylmethoxy)carbonyl]-5'-deoxy-5-fluorocytidine, 2',3'-di-0-acetyl-5'-deoxy-5-fluoro-N4-[(2-phenylethoxy)carbonyl]cytidine, 5'-deoxy-5-fluoro-N4-(isobutoxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4- [(2-propylpentyl)oxycarbonyl] cytidine, δ'-deoxy-N4- [(2-ethylhexyl)oxycarbonyl] -5'-fluorocytidine, δ'-deoxy-δ-fluoro-N4-(heptyloxycarbonyl)cytidine, N4-[(2-cyclohexylethoxy)carbonyl]-δ'-deoxy-δ-fluorocytidine, N4- [(3-cyclohexylpropyl)oxycarbonyl] -δ'-deoxy-δ-fluorocytidine, N4-(cyclohexyloxycarbonyl)-δ'-deoxy-δ-fluorocytidine, δ'-deoxy-δ-fluoro-N4- [(3-phenylpropyl)oxycarbonyl] cytidine, δ'-deoxy-δ-fluoro-N4- [(2-methoxyethoxy)carbonyl] cytidine, N4-(butoxycarbonyl)-δ'-deoxy-δ-fluorocytidine 5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, 2',2'-difluorodeoxycytidine, 5-fluoro- 1-tetrahy dr ofuran- 1 -yluracil , 2'-deoxy-2'-methylidene-δ-fluorocytidine, 2'-deoxy-2'-cyano-δ-fluorocytidine and as well as hydrate or solvate thereof.
The above mentioned specific compounds are described in U.S. patent Nos. 4,071,680 and 4,966,891, European Patent Nos. 602290-A1, K. Takenuki et al. J. Med. Chem. 31, 1063 (1988), K. Yamagami et al. Cancer Research 51, 2319 (1991) and A. Matsuda et al. J. Med. Chem. 34, 2917 (1991), respectively, and those compounds can be produced according to the method described in the respective references or the analogous method thereof.
IL-12 is a heterodimeric cytokine which is produced by antigen presenting cells and serves as a pivotal regulator of T and NK cell function (cf. Stern, A.S. et al. Proc. Natl. Acad. Sci. USA. (1990) 87, 6808-6812 and Kobayashi, M. et al. J. Exp. Med. (1989) 170, 827-845). Biological activities associated with IL-12 include its ability to enhance the lytic activity of
natural killer/lymphokine activated killer cells, to induce the secretion of interferon-g (IFN-g) by both resting and activated T and NK cells, to stimulate the proliferation of activated T and NK cells, to facilitate cytotoxic T lymphocyte responses and to play a critical and unique role in promoting Th-1 type cytokine responses, thereby facilitating cell-mediated immunity (cf. Brunda, M. J. J. Leukocyte Biol. (1994) 55, 280-288 and Taniguchi, G. Blood (1994) 84, 4008-4027).
IL-12, both human type and murine type, is composed of two disulfide- bonded glycoprotein subunits approximately 35 KDa and 40 KDa in size. cDNAs encoding each subunit of IL-12 have been cloned and coexpressed in Chinese Hamster Ovary (CHO) cells to yield the secreted, bioactive, heterodimeric lymphokine (Gubler, U. et al. Proc. Natl. Acad. Sci. USA. (1991) 88, 4143-4147 and Schaenhaut, D.S. et al. J. Immunol. (1992) 148, 3433- 3440) A clone of transfected CHO cells secreting recombinant IL-12 was selected. Recombinant IL-12 was purified from the culture supernatant of CHO cells grown in a serum-free medium, by ion exchange and gel filtration chromatography.
The pharmaceutical compostion of the present invention can be administered in any form, for example, tablets, pills, suppositories, capsules, granules, powders, etc. or emulsions. The pharmaceutical composition of the present invention are especially suitable for intramuscular, subcutaneous, or intravenous administration. Pharmaceutically acceptable carriers and excipients useful in formulating the pharmaceutical composition of the present invention are those commonly used. Pharmaceutically acceptable materials can be an organic or inorganic inert carrier material suitable for enteral, percutaneous or parenteral administration such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols and petroleum jelly. The pharmaceutical composition provided by the present invention can be administered orally, e.g. in form of tablets, capsules, pills, powders, granules, solutions, syrups, suspensions or elixirs. The administration can also be carried out parenterally, e.g. in form of sterile solutions, suspensions or emulsions; or locally, e.g. in form of solutions, suspensions, salves, powders or aerosols. The pharmaceutical composition can be sterilized and/or can contain further adjuvants such as preserving,
stabilizing, setting, emulsifying agents, flavor-improving, salts for variation of the osmotic pressure or substances acting as buffers.
The synergistic antitumor pharmaceutical composition of the present invention comprises a single pharmaceutical composition as well as a kit of pharmaceutical compositions each containing the individual active ingredient in a desirable dosage form, thus, the present invention is also concerned with a kit for the treatment of colorectal cancer, breast cancer, stomach cancer, lung cancer, cervical cancer, bladder cancer and other malignant diseases which comprises as a first pharmaceutical composition containing an effective amount of IL-12 and a pharmaceutically acceptable carrier, and as a second pharmaceutical composition containing an effective amount of pyrimidine nucleoside derivative, as well as hydrate or solvate thereof and a pharmaceutically acceptable carrier.
Dosage ranges for the pharmaceutical composition of the present invention can easily be determined by one skilled in the art, and depend on the route of administration, the age, weight and condition of the patient and the particular disease to be treated. In the case of oral, rectal or parenteral administration for adults, an approximate range from about 0.05 mg/body/day to about 500 mg/body/day of IL-12, and about 50 mg/body/day to about 20,000 mg/body/day of pyrimidine nucleoside generally range from about 1:100 to about 1:400,000. A weight ratio from about 1:1,000 to about 1:10,000 is preferred. Rectal administration and intravenous injection are preferred routes of administration of the pharmaceutical composition according to the present invention.
The pharmaceutical compositions of the present invention are useful for the treatment of colorectal cancer, breast cancer, stomach cancer, lung cancer, cervicial cancer, bladder cancer, and other malignant diseases and the like.
The synergistic antitumor activity of the pharmaceutical composition of the present invention is evident from the tests described hereinafter.
(1) Up-regulation of the enzyme for the activation of doxifluridine and 5'- deoxy-5-fluoro-N4-(n-pentyloxycarbonyl)cytidine (capecitabine) by mIL-12.
Six weeks old female C57BL/6 mice or male BALB/c mice were inoculated with A7δδ mammary adenocarcinoma (2 x 10*^ cells) or with Meth A fibrosarcoma (5 x 10*^ cells), respectively. The mice were given s.c. mouse IL-12 (mIL-12) at 0.1 mg/mouse or vehicle (0.1 mg/ml of mouse serum albumin dissolved in phosphate-buffered saline) daily for 7 days starting at day 7 and day 8, respectively, after the tumor inoculation. One day thereafter, PyNPase activity in the tumor tissues was measured as described in Eda et al. Cancer Chemother. Pharmacol. 1993; 32:333. Mouse IFN-g (m IFN-g) levels in the tumor tissue were also measured by a commercially available ELISA system (Intertest g, Genzyme).
As Table 1 shows, mIL-12 enhanced PyNPase activity 11.9 fold in A75δ tumors and 2.4 fold in Meth A tumors. This is probably the result of the up- regulation of mIFN-g, which is an up-regulator of PyNPase.
Table 1
Up-regulation of PyNPase and mIFN-g by mIL-12
PyNPase mIFN-g
Tumor Model Administration Activity Levels
(μg δ-FU/mg/hr) (ng/g tissue)
A7δ5 mammary ca. vehicle 4.4±4.6 a) <2.0 mIL-12 52.3+28.8 * 46.8±11.7 *
Meth A fibrosarcoma vehicle 21.4±2.6 <1.1 mIL-12 51.7±9.4 * 6.7+2.1 *
* Statistically significant difference from the vehicle groups (p<0.0δ, Student t-test). a) Mean ± SD of 6 mice.
2) Selective induction of mIFN-g production by mIL-12 in the tumor tissue.
Six weeks old female C57BL/6 mice were inoculated with A7δδ mammary adenocarcinoma (2 x 105 cells). The mice were given s.c. mIL-12 at 0.1 mg/mouse or vehicle (0.1 mg/ml of mouse serum albumin dissolved in phosphate-buffered saline) daily for 7 days starting at day 6 after the tumor inoculation. One day thereafter, mIFN-g levels in the serum and tissue homogenates of tumor and other organs were measured by ELISA system as mentioned above.
As Table 2 shows, mIL-12 greatly increased mIFN-g levels in tumors as compared with those in normal organs. The tumor tissue level of mIFN-g is 3 to 7 fold higher than those of normal tissues so far examined and 50 fold higher than those in the circulation. These results suggest that mIL-12 up- regulates PyNPase selectively in the tumor tissue, through the up-regulation of mIFN-g production by IL-12 selectively in tumor tissues.
Table 2
Selective induction of mIFN-g production by mIL-12 in tumor tissues
mIFN-g levels (ng/g tissue) -l
Organs treatment of the mice vehicle mIL-12
tumor 3.2 ± 0.9 32.7 ± 9.8 *
serum 0.27 ± 0.05 0.66 ± 0.22 * small intestine <2.δ 5.3 ± 4.0 large intestine 2.8 ± 0.8 4.3 ± 0.5 * spleen 2.9 ± 0.δ 9.3 ± 1.9 * liver 2.1 ± 1.0 4.2 ± 0.6 * kidney 5.1 ± 1.1 7.5 ± 1.4 * thymus ") 6.2 10.3
* ; Significantly higher than vehicle group (p<0.05). a) ; Mean ± SD. n=4 and δ in vehicle and mIL-12 group, respectively, with an exception of thymus. °) ; Values obtained from a combined homogenate of 4 thymuses.
(3) Antitumor effects of combination of doxifluridine or capecitabine and IL-12
1) A7δδ mammary adenocarcinoma model
A7δδ (2 x 105 cells) was inoculated s.c. into female Cδ7BL/6 mice. The mice were given mIL-12 (0.03 μg/mouse, s.c), doxifluridine (1.5 mmol/kg, p.o.) and their combination, daily for 4 weeks, starting from day 9 after the tumor inoculation.
Doxifluridine as a single agent did not show activity in tumor growth inhibition because A75δ tumor has only low levels of PyNPase, whereas
mIL-12 was effective (Table 3). mIL-12 in combination with doxifluridine was much more effective than mIL-12 alone and regressed the tumor.
The combination effect was more obvious when the survival period was° observed (Table 4). Doxifluridine was not effective either in prolongation of the survival period, and IL-12 slightly prolonged the survival period. In contrast, IL-12 and doxifluridine in combination prolonged the survival period much longer than IL-12 alone and some mice were cured (3/5).
Table 3
Antitumor activity of doxifluridine, mIL-12 and their combination in A75δ mammary adenocarcinoma model.
Treatment Tumor Volume (m ^) % Tumor Growth on day 2δ a) vs. Control vs. mIL-12 alone
Control 8969 ± 4169 °) 100
doxifluridine 8380 ± 2907 93
mIL-12 2399 ± lδ67 c) 22 100
doxifluridine 216 ± 187 c) d) - 4 - 16
+ mIL-12
a) Tumor volume of 26 days after tumor inoculation was indicated, since thereafter death of mice in the control group were observed because of large tumor burden. The tumor volume on day 9 when the treatment initiated was δl3 ± 300 πm_3. b) Mean ± SD c) Significantly different from the control group, p < O.Oδ d) Significantly different from the mIL-12 group, p < O.Oδ
Table 4
Survival of mice treated with doxifluridine, mIL-12 and their combination in A7δδ mammary adenocarcinoma model
Treatment Median Survival Increase in Survivors
Days (range) Life Span % on Day lδ3
Control 28 (23 - 42) 0 o/δ doxifluridine 29 (22 - 36) 4 0/5
mIL-12 49 (43 - 55) a-* 7δ 0/5
doxifluridine
+ mIL-12 >153 (δl - >lδ3) a) ) >446 3/5
a) Significantly different from the control group, p < 0.05 b) Significantly different from the mIL-12 group, p < 0.05
2) Meth A fibrosarcoma model
Meth A fibrosarcoma (5 x 105 cells) was inoculated s.c. into male BALB/c mice. The mice were given doxifluridine (O.δ mmol/kg, p.o.), capecitabine (1.0 mmol/kg, p.o.), δ-fluorouracil (0.07δ mmol kg, p.o.), mIL-12 (0.03 μg/mouse, s.c), and their combination, daily for 3 weeks, starting from day 8 after the tumor inoculation.
Three fluoropyrimidines or mIL-12 as single agents showed moderate activity in tumor growth inhibition, at the doses employed. mIL-12 in combination with either doxifluridine or capecitabine showed more potent antitumor activity than either drug alone (p < O.Oδ). On the other hand, mIL-12 and δ-fluorouracil in combination was only slightly more effective than either drug alone (not statistically significant).
Table 5
Antitumor activity of three fluoropyrimidines (doxifluridine, capecitabine, 5-fluorouracil), mIL-12 and their combination in Meth A fibrosarcoma model.
Treatment Tumor Volume (mm3) % Tumor Growth on day 29 a) vs. Control vs. mIL-12
Control 10489 ± 2054 b) 100 doxifluridine 5170 ± 887 c) 48 - capecitabine 4941 ± 1397 c) 46 -
5-fluorouracil 6168 ± 530 c) 58 - mIL-12 4584 ± 1198 °) 42 100 mIL-12 + doxifluridine 1912 ± 1322 cde) 16 39 mIL-12 + capecitabine 2199 ± 1329 cde) 19 45 mIL-12 + 5-fluorouracil 3503 ± 1785 ∞) 32 75
a) Tumor volume of 29 days after tumor inoculation was indicated. The mean tumor volume on day 8 when the treatment initiated was 230 mm3. b) Mean ± SD c) Significantly different from the control group, p < 0.05 d) Significantly different from the mIL-12 alone group, p < 0.05 e) Significantly different from the corresponding fluoropyrimidine alone group, p < 0.05
The following examples illustrate a pharmaceutical preparation of the present invention and do not limit the scope of the present invention.
Example 1
An injectable solution containing the following ingredients was manufactured in a conventional manner: doxifluridine 1000 mg hIL-12 50 μg
NaCl 41.4 mg
NaH2P04 16.2 mg
Na2HPθ4 36.7 mg polysorbate 80 4 mg
adjust pH 7.0 with 1.2 N HC1 or 1 N NaOH adjust total volume of 20 ml with distilled water for injection
Example 2
An injectable solution each containing the following ingredients was manufactured in a conventional manner: capecitabine 100 mg hIL-12 δO μg
NaCl 718.2 mg
NaH2P04 81 mg
Na2HP04 188 mg polysorbate 80 20 mg
adjust pH 7.0 with 1.2 N HC1 or 1 N NaOH adjust total volume of 100 ml with distilled water for injection
Example 3
A kit having the following components A and B for treatment of colorectal cancer was manufactured in a conventional manner: Component A
(granule for oral administration) capecitabine 150 mg hydroxypropylmethyl cellulose 2910 4.5 mg crystalline cellulose 14.7 mg croscarmellose sodium (Ac-Di-Sol) 6.0 mg magnesium stearate 1.8 mg coating agent 3.0 mg
Total 180 mg
Component B
(sterile solution for injection) hIL-12 0.2-20 mg
NaCl 116 mg
NAH2PO4 62.2 mg Na2HP04 115.8 mg polysorbate 80 4 mg
adjust pH to 7.0 with 1.2 N HC1 or IN NaOH adjust total volume to 20 ml with water for injection
Claims
1. A synergistic antitumor pharmaceutical composition comprising an effective amount of interleukin- 12 and a pyrimidine nucleoside derivative as well as a hydrate or solvate thereof that is converted into fluorouracil or its derivative, and a pharmaceutically acceptable carrier.
2. The composition of claim 1, wherein the pyrimidine nucleoside is an uridine, cytidine or its derivative represented by the follwoing formula (I) or (II), respectively
wherein Rl is hydrogen or a radical which is easily hydrolyzable under physiological conditions; R-2 is hydrogen, cyano, fluorine, lower alkyl or lower alkylidene which may be substituted with one or two fluorine atom(s), or OR*; and R*3 is lower alkyl, hydroxymethyl, or CH2OR1, as well as hydrate or solvate thereof.
3. The composition of claim 2, wherein the easily hydrolyzable radical is R4CO-, R OCO- or R SCO-, wherein R4 is alkyl, cycloalkyl, aralkyl or aryl.
4. The composition of claim 3, wherein the alkyl, cycloalkyl, aralkyl or aryl radical represented by R4 is a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven], or a radical of the formula (CH2)n-Y[ which n is an integer from 0 to 4, when Y is cyclohexyl, or n is an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl]. δ. The composition of claim 2, wherein the pyrimidine nucleoside derivative is selected from the group consisting of:
δ'-deoxy-δ-fluorouridine, 5-deoxy-5-fluorocytidine,
5'-deoxy-N4-(3,5-dimethoxybenzoly)-δ-fluorocytidine, δ'-deoxy-N4-(3,δ-dimethylbenzoly)-δ-fluorocytidine, δ'-deoxy-N4- [(2,4-dichlorophenyl)acetyl] -δ-fluorocytidine, δ'-deoxy-N4-(indol-2-ylacetyl)-δ-fluorocytidine, δ'-deoxy-δ-fluoro-N4-(3,4,δ-trimethylbenzoly)cytidine, δ'-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 5'-deoxy-δ-fluoro-N4-(hexyloxycarbonyl)cytidine, δ'-deoxy-δ-fluoro-N4-(isopentyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-(neopentyloxycarbonyl)cytidine, δ'-deoxy-δ-fluoro-N4- [( 1, l,2-trimethylpropoxy)carbonyl] cytidine, δ'-deoxy-N4-[(3,3-dimethylbutoxy)carbonyl]-δ-fluorocytidine, δ'-deoxy-δ-fluoro-N4- [( l-isopropyl-2-methylpropoxy)carbonyl] cytidine, δ'-deoxy-N4-[(2-ethylbutyl)oxycarbonyl]-δ-fluorocytidine, N4-[(cyclohexylmethoxy)carbonyl]-δ'-deoxy-δ-fluorocytidine, 5'-deoxy-5-fluoro-N4-[(2-ρhenylethoxy)carbonyl] cytidine,
2l,3,-di-O-acetyl-δ'-deoxy-δ-fluoro-N4-(propoxycarbonyl)cytidine, 2',3'-di-O-acetyl-N4-(butoxycarbonyl)-δ'-deoxy-δ-fluorocytidine, 2',3'-di-0-benzoyl-N4-(butoxycarbonyl)-δ'-deoxy-δ-fluorocytidine, 2',3'-di-0-acetyl-δ'-deoxy-δ-fluoro-N4-(pentyloxycarbonyl)cytidine, 2',3'-di-0-acetyl-δ'-deoxy-δ-fluoro-N4-(isopentyloxycarbonyl)cytidine, 2',3'-di-0-acetyl-δ'-deoxy-δ-fluoro-N4-(hexyloxycarbonyl)cytidine, 2',3,-di-O-acetyl-δ,-deoxy-N4-[(2-ethylbutyl)oxycarbonyl]-δ-fluorocytidine, 2',3l-di-O-acetyl-N4-[(cyclohexylmethoxy)carbonyl]-δ'-deoxy-δ-fluorocytidine, 2',3'-di-0-acetyl-δ'-deoxy-δ-fluoro-N4-[(2-phenylethoxy)carbonyl]cytidine, δ'-deoxy-δ-fluoro-N4-(isobutoxycarbonyl)cytidine, δ'-deoxy-δ-fluoro-N4- [(2-propylpentyl)oxycarbonyl] cytidine, δ'-deoxy-N4-[(2-ethylhexyl)oxycarbonyl]-5'-fluorocytidine,
5'-deoxy-δ-fluoro-N4-(heptyloxycarbonyl)cytidine,
N4- [(2-cyclohexylethoxy)carbonyl] -δ'-deoxy-δ-fluorocytidine, N4- [(3-cyclohexylpropyl)oxycarbonyl] -δ'-deoxy-δ-fluorocytidine, N -(cyclohexyloxycarbonyl)-δ'-deoxy-δ-fluorocytidine, δ'-deoxy-δ-fluoro-N4- [(3-phenylpropyl)oxycarbonyl] cytidine, δ'-deoxy-δ-fluoro-N4-[(2-methoxyethoxy)carbonyl]cytidine, N4-(butoxycarbonyl)-δ'-deoxy-δ-fluorocytidine, δ'-deoxy-δ-fluoro-N4-(pentyloxycarbonyl)cytidine, 2' ,2 '-difluorodeoxycytidine , δ-fluoro-1-tetrahydrofuran-l-yluracil, 2'-deoxy-2'-methylidene-δ-fluorocytidine, 2'-deoxy-2'-cyano-δ-fluorocytidine as well as hydrates or solvates thereof.
6. The composition any one of claims 1 to δ, wherein the weight ratio of interleukin- 12 to pyrimidine nucleoside is from about 1:100 to about 1:400,000.
7. The composition any one of claims 1 to δ, wherein the weight ratio of interleukin- 12 to pyrimidine nucleoside is from about 1:1,000 to about 1:10,000.
8. A synergistic antitumor pharmaceutical composition for the treatment of colorectal cancer, brest cancer, stomach cancer, lung cancer, cervical cancer, bladder cancer and other malignant diseases comprising an effective amount of interleukin-12 and a pyrimidine nucleoside as well as a hydrate or solvate thereof, that are converted into fluorouracil or other active metabolite by pyrimidine nucleoside phosphorylase, and a pharmaceutically acceptable carrier.
9. The composition of claim 8, wherein the pyrimidine nucleoside is an uridine, cytidine or its derivative represented by the following formula (I) or
(II), respectively as defined in claim 2 as well as a hydrate or solvate thereof.
10. The composition of claim 8, wherein the easily hydrolyzable radical is R4CO-, R4OCO- or R4SCO-, wherein R4 is alkyl, cycloalkyl, aralkyl or aryl.
11. The composition of claim 10, wherein the alkyl, cycloalkyl, aralkyl or aryl radical represented by R4 is a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven], or a radical of the formula (CH2)n-Y[ which n is an integer from 0 to 4, when Y is cyclohexyl, or n is an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl] .
12. The composition of claim 9, wherein the pyrimidine nucleoside derivative is selected from the compounds defined in claim 5.
13. The composition any one of claims 8 to 12, wherein the weight ratio of interleukin- 12 to pyrimidine nucleoside is from about 1:100 to about 1:400,000.
14. The composition any one of claims 8 to 12, wherein the weight ratio of interleukin- 12 to pyrimidine nucleoside is from about 1:1,000 to about 1:10,000.
lδ. A method of treating colorectal cancer, brest cancer, stomach cancer, lung cancer, cervical cancer, bladder cancer and other malignant diseases which comprises administering a synergistic antitumor pharmaceutical composition comprising an effective amount of interleukin- 12 and pyrimidine nucleoside or as well as hydrate or solvate thereof, that are converted into fluorouracil or other active metabolite by pyrimidine nucleoside phosphorylase, and a pharmaceutically acceptable carrier.
16. The method of claim lδ, wherein the pyrimidine nucleoside is an uridine, cytidine or its derivative represented by the following formula (I) or (II), respectively, as defined in claim 2, as well as a hydrate or solvate thereof.
17. The method of claim 16, wherein the easily hydrolyzable radical is R4CO-, R4OCO- or R4SCO-, wherein R4 is alkyl, cycloalkyl, aralkyl or aryl.
18. The method of claim 17, wherein the alkyl, cycloalkyl, aralkyl or aryl radical represented by R4 is a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven], or a radical of the formula (CH2)n-Y -in which n is an integer from 0 to 4, when Y is cyclohexyl, or n is an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl].
19. The composition of claim lδ, wherein the pyrimidine nucleoside derivative is the one selected from the compounds defined in claim δ, as well as a hydrate or solvate thereof.
20. The method any one of claims lδ to 19, wherein the weight ratio of interleukin- 12 to pyrimidien nucleoside is from about 1:100 to about 1:400,000.
21. The method any one of claims lδ to 19, wherein the weight ratio of interleukin-12 to pyrimidine nucleoside is from about 1:1,000 to 1:10,000.
22. A kit for the treatment of colorectal cancer, breast cancer, stomach cancer, lung cancer, cervical cancer, bladder cancer and other malignant diseases which comprises as a first pharmaceutical composition containing an effective amount of interleukin- 12 and a pharmaceutically acceptable carrier, and as a second pharmaceutical composition containing an effective amount of a pyrimidine nucleoside derivative, as well as a hydrate or solvate thereof and a pharmaceutically acceptable carrier.
23. The use of interleukin- 12 and a pharmaceutically acceptable carrier, and as a second pharmaceutical composition containing an effective amount of a pyrimidine nucleoside derivative, as well as a hydrate or solvate thereof for the manufacture of pharmaceutical compositions as claimed in claims 8 or 22.
***
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU59982/96A AU5998296A (en) | 1995-05-26 | 1996-05-15 | Compositions of interleukin and pyrimidine nucleosides |
| JP8535342A JPH10506641A (en) | 1995-05-26 | 1996-05-15 | Composition of interleukin 12 and pyrimidine nucleoside |
| BR9608779A BR9608779A (en) | 1995-05-26 | 1996-05-15 | Compositions of nucleoside interleukin and pyrimidine |
| EP96917379A EP0828508A2 (en) | 1995-05-26 | 1996-05-15 | Compositions of interleukin and pyrimidine nucleosides |
| MXPA/A/1997/008915A MXPA97008915A (en) | 1995-05-26 | 1997-11-19 | Compositions of interleucine and nucleosides of pirimid |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95108063.9 | 1995-05-26 | ||
| EP95108063 | 1995-05-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996037214A2 true WO1996037214A2 (en) | 1996-11-28 |
| WO1996037214A3 WO1996037214A3 (en) | 1997-01-09 |
Family
ID=8219298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/002088 WO1996037214A2 (en) | 1995-05-26 | 1996-05-15 | Compositions of interleukin and pyrimidine nucleosides |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0828508A2 (en) |
| JP (1) | JPH10506641A (en) |
| CN (1) | CN1184430A (en) |
| AR (1) | AR005417A1 (en) |
| AU (1) | AU5998296A (en) |
| BR (1) | BR9608779A (en) |
| CA (1) | CA2220837A1 (en) |
| TR (1) | TR199701435T1 (en) |
| WO (1) | WO1996037214A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0882734A2 (en) * | 1997-06-02 | 1998-12-09 | F. Hoffmann-La Roche Ag | 5'-Deoxy-cytidine derivatives |
| US6114520A (en) * | 1997-06-02 | 2000-09-05 | Hoffmann-La Roche Inc. | 5'-deoxy-cytidine derivatives |
-
1996
- 1996-05-15 CA CA002220837A patent/CA2220837A1/en not_active Abandoned
- 1996-05-15 EP EP96917379A patent/EP0828508A2/en not_active Withdrawn
- 1996-05-15 CN CN96194016A patent/CN1184430A/en active Pending
- 1996-05-15 JP JP8535342A patent/JPH10506641A/en active Pending
- 1996-05-15 TR TR97/01435T patent/TR199701435T1/en unknown
- 1996-05-15 AU AU59982/96A patent/AU5998296A/en not_active Abandoned
- 1996-05-15 WO PCT/EP1996/002088 patent/WO1996037214A2/en not_active Application Discontinuation
- 1996-05-15 BR BR9608779A patent/BR9608779A/en not_active Application Discontinuation
- 1996-05-22 AR ARP960102652A patent/AR005417A1/en unknown
Non-Patent Citations (2)
| Title |
|---|
| PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, 36 (0). 01-03-1995. 480., XP000605926 EMI Y ET AL: "Interleukin-12 (IL-12) enhances antitumor activity of chemotherapy and radiotherapy in murine models" * |
| RESEARCH IN IMMUNOLOGY, 01-01-1995, 146/7-8 (506-514), FRANCE, XP000607088 JACOBSEN S.E.W.: "Il12, a direct stimulator and indirect inhibitor of haematopoiesis" * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0882734A2 (en) * | 1997-06-02 | 1998-12-09 | F. Hoffmann-La Roche Ag | 5'-Deoxy-cytidine derivatives |
| US6114520A (en) * | 1997-06-02 | 2000-09-05 | Hoffmann-La Roche Inc. | 5'-deoxy-cytidine derivatives |
| US6211166B1 (en) * | 1997-06-02 | 2001-04-03 | Hoffman-La Roche Inc. | 5′-deoxy-cytidine derivative administration to treat solid tumors |
| EP0882734A3 (en) * | 1997-06-02 | 2004-08-25 | F. Hoffmann-La Roche Ag | 5'-Deoxy-cytidine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5998296A (en) | 1996-12-11 |
| AR005417A1 (en) | 1999-06-23 |
| JPH10506641A (en) | 1998-06-30 |
| EP0828508A2 (en) | 1998-03-18 |
| WO1996037214A3 (en) | 1997-01-09 |
| CN1184430A (en) | 1998-06-10 |
| MX9708915A (en) | 1998-03-31 |
| BR9608779A (en) | 1999-07-06 |
| CA2220837A1 (en) | 1996-11-28 |
| TR199701435T1 (en) | 1998-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2590248B2 (en) | Antiviral, antitumor, antimetastasis, immune system enhancing nucleosides and nucleotides | |
| US6344447B2 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| US6509320B1 (en) | Purine L-nucleosides, analogs and uses thereof | |
| US5736531A (en) | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides | |
| US4879111A (en) | Treatment of infections with lymphokines | |
| EP0693077B1 (en) | Antiviral compounds | |
| US7524831B2 (en) | Treatments for Flaviviridae virus infection | |
| CA2111571C (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| AU2486088A (en) | Antiviral antitumor antimetastatic immune system enhancing nucleosides and nucleotides | |
| WO1994026761A1 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| IL112373A (en) | Use of interleukin-12 for the preparation of a pharmaceutical composition for preventing, ameliorating and treating graft-versus-host disease | |
| KR100418483B1 (en) | A composition comprising nonionic surfactants for improvement of hematopoiesis and therapeutic method using the same | |
| EP0231819B1 (en) | Pharmaceutical agent for the treatment of myelogenous leukemia | |
| AU732120B2 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
| EP0828508A2 (en) | Compositions of interleukin and pyrimidine nucleosides | |
| US7776838B1 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| MXPA97008915A (en) | Compositions of interleucine and nucleosides of pirimid | |
| EP1072607A2 (en) | Purine L-nucleosides, analogs and uses therof | |
| EP0594223A1 (en) | Therapeutic nucleosides | |
| Brach et al. | Modulation of cytotoxicity and differentiation-inducing potential of arabinofuranosylcytosine in myeloid leukemia cells by hematopoietic cytokines | |
| AU751742B2 (en) | Purine L-nucleosides, analogs and uses thereof | |
| CA2323791A1 (en) | Purine l-nucleosides, analogs and uses thereof | |
| KR20070015642A (en) | 3-β-D-ribofuranosylthiazolo [4,5-d] pyrididiminenucleosides and uses thereof | |
| NZ505553A (en) | 8-substituted alpha or beta L-guanosine analogs and uses thereof | |
| CA2322053A1 (en) | Novel nucleosides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 96194016.6 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AU BB BG BR CA CN CZ EE GE HU IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AU BB BG BR CA CN CZ EE GE HU IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase in: |
Ref document number: 2220837 Country of ref document: CA Ref document number: 2220837 Country of ref document: CA Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1996917379 Country of ref document: EP Ref document number: PA/a/1997/008915 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 97/01435 Country of ref document: TR |
|
| WWP | Wipo information: published in national office |
Ref document number: 1996917379 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1996917379 Country of ref document: EP |